1-833-ENHERTU (1-833-364-3788)

Affording Your Medicine

Learn more about options to make your prescribed ENHERTU treatment more affordable

Patient Savings Program

Patient Assistance Programs

Independent Foundations

ENHERTU Patient Savings Program for commercially insured patients

If you have commercial insurance, the ENHERTU Patient Savings Program may help you with out-of-pocket costs. Talk to your doctor to sign up for the program or call ENHERTU4U at 1-833-ENHERTU (1-833-364-3788).

If you do not have commercial insurance, please see the Patient Assistance Programs and Independent Foundations tabs.

Eligible patients may pay as little as $0 per ENHERTU prescription.

Eligible patients may pay as little as $0 per ENHERTU prescription, up to $26,000 per year to help with ENHERTU out-of-pocket costs. The annual benefit can be used for the cost of the drug itself, and may also cover up to $100 in infusion costs per administration.* There are no income requirements to participate in the program.

*Patients who are residents of Massachusetts, Michigan, Minnesota, or Rhode Island are not eligible for infusion assistance.

See below for full patient eligibility. Restrictions apply.

Do I have commercial insurance?

If you have commercial or private insurance, that means you get it from your job, your parent’s or spouse’s job, or healthcare exchange. You do not get your insurance from the government.

See below for full patient eligibility. Restrictions apply.

If you are uninsured, underinsured, or a Medicare patient and you cannot afford your medicine, you may be able to get help from our Patient Assistance Programs.

Patient Assistance Programs (PAP) can provide ENHERTU for free if you qualify. Eligibility rules apply.

Talk to your doctor or call ENHERTU4U to find out more at 1-833-ENHERTU (1-833-364-3788).

See below for full eligibility. Restrictions apply.

ENHERTU PAP enrollment form

PAP Enrollment Form

To determine if you are eligible for the ENHERTU Patient Assistance Program, print out the PAP enrollment form and work with your doctor to complete it. It can be faxed to 1-833-904-1851 or mailed to:
ENHERTU Patient Assistance Programs, PO Box 221285, Charlotte, NC 28222.

Download PAP Enrollment Form - English Download PAP Enrollment Form - Spanish

Eligibility

In order to determine if you may be eligible for our programs, please review the important information below.

You must have been prescribed ENHERTU.

You must be a resident of the US.

You must not have insurance, private or government, that covers ENHERTU.

You must not be receiving any other assistance to help pay for ENHERTU.

Your annual income must be at or below a certain level.

If you are a Medicare Beneficiary:

  • You must not be eligible for or enrolled in Low Income Subsidy (LIS) for Medicare Part D
  • You must have spent at least 3% of your annual household income on prescription medicines in the current year

If you have experienced a life-changing event in the past year, and your financial documentation does not accurately reflect your current situation, we encourage you to apply to Patient Assistance Programs. You may still meet the criteria to enroll. Some examples of this type of event would be:

  • Loss of employment
  • Change in income
  • Loss of, or change in, prescription drug coverage
  • Change in marital status
  • Change in household number

General referral to independent charitable foundations

Assistance may be available through independent foundations such as those listed below. Foundations can provide a variety of assistance types: co-pay, transportation, premium, patient education, etc.

These foundations are not associated with AstraZeneca or Daiichi Sankyo; specific details and eligibility requirements can be found directly at the foundations’ websites.

Patient Access Network Foundation

Good Days Fund

Patient Advocate Foundation

CancerCare Co-Payment Assistance Foundation

The Assistance Fund

AstraZeneca and Daiichi Sankyo do not endorse or guarantee reimbursement or support from any of the organizations listed above.

Am I eligible?

  • You must be a resident of the United States or Puerto Rico
  • You must have commercial insurance that covers ENHERTU, but not the full cost of the medication
  • You are ineligible if prescriptions are paid by any state or other federally funded programs, including, but not limited to, Medicare Part B, Medicare Part D, Medicaid, Medigap, VA, or TRICARE, or where prohibited by law
  • Offer is invalid for all transactions and claims submitted more than 120 days following the date of service
  • Eligibility rules apply. Additional restrictions may apply

How to enroll

Talk to your doctor about signing up for the ENHERTU Patient Savings Program.

If you need help signing up or have questions, please contact ENHERTU4U at 1-833-ENHERTU (1-833-364-3788).

ENHERTU4U: Patient Access to Treatment

1-833-ENHERTU (1-833-364-3788)

Important Safety Information,
including Boxed WARNINGSSee more

Important Safety Information,
including Boxed WARNINGSSee less

What is the most important information I should know about ENHERTU?

ENHERTU can cause serious side effects, including:

Lung problems that may be severe, life-threatening or that may lead to death. If you develop lung problems your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs and symptoms:

  • Cough
  • Trouble breathing or shortness of breath
  • Fever
  • Other new or worsening breathing symptoms (e.g., chest tightness, wheezing)

Low white blood cell count (neutropenia). Low white blood cell counts are common with ENHERTU and can sometimes be severe. Your healthcare provider will check your white blood cell counts before starting ENHERTU and before starting each dose. Tell your healthcare provider right away if you develop any signs or symptoms of an infection or have fever or chills during treatment with ENHERTU.

Heart problems that may affect your heart’s ability to pump blood. Your healthcare provider will check your heart function before starting treatment with ENHERTU. Tell your healthcare provider right away if you get any of the following signs and symptoms:

  • New or worsening shortness of breath
  • Coughing
  • Feeling tired
  • Swelling of your ankles or legs
  • Irregular heartbeat
  • Sudden weight gain
  • Dizziness or feeling light-headed
  • Loss of consciousness

Your healthcare provider will check you for these side effects during your treatment with ENHERTU. Your healthcare provider may reduce your dose, delay treatment or completely stop treatment with ENHERTU if you have severe side effects.

Harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ENHERTU.

  • If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with ENHERTU.
  • Females who are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for at least 7 months after the last dose.
  • Males who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for at least 4 months after the last dose.

Before you receive ENHERTU, tell your healthcare provider about all of your medical conditions, including if you:

  • Have lung or breathing problems.
  • Have signs or symptoms of an infection.
  • Have or have had any heart problems.
  • Are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes into your breast milk. Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive ENHERTU?

  • You will receive ENHERTU into your vein through an intravenous (IV) line by your healthcare provider.
  • ENHERTU is given 1 time every three weeks (21-day treatment cycle).
  • Your healthcare provider will decide how many treatments you need.
  • Your healthcare provider may slow down or temporarily stop your infusion of ENHERTU if you have an infusion-related reaction, or permanently stop ENHERTU if you have severe infusion reactions.
  • If you miss a planned dose of ENHERTU, call your healthcare provider right away to schedule an appointment. Do not wait until the next planned treatment cycle.

What are the possible side effects of ENHERTU?

ENHERTU can cause serious side effects. See "What is the most important information I should know about ENHERTU?"

The most common side effects of ENHERTU, when used in people with breast cancer, include:

  • Nausea
  • Low white blood cell counts
  • Low red blood cell counts
  • Feeling tired
  • Vomiting
  • Hair loss
  • Increased liver function tests
  • Low platelet counts
  • Constipation
  • Decreased appetite
  • Diarrhea
  • Low levels of blood potassium
  • Cough

The most common side effects of ENHERTU, when used in people with stomach cancer, include:

  • Low red blood cell counts
  • Low white blood cell counts
  • Low platelet counts
  • Nausea
  • Decreased appetite
  • Increased liver function tests
  • Feeling tired
  • Diarrhea
  • Low levels of blood potassium
  • Vomiting
  • Constipation
  • Fever
  • Hair loss

ENHERTU may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.

These are not all of the possible side effects of ENHERTU. Call your doctor for medical advice about side effects. You may report side effects to Daiichi Sankyo at 1-877-437-7763 or to FDA at 1-800-FDA-1088.

What is ENHERTU?

ENHERTU is a prescription medicine used in adults to treat human epidermal growth factor receptor 2 (HER2)-positive:

  • Breast cancer that cannot be removed by surgery or that has spread to other parts of your body (metastatic), and who have received two or more prior anti-HER2 breast cancer treatments.

    ENHERTU was FDA approved for this use based on a clinical study that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

  • Stomach cancer called gastric or gastroesophageal junction (GEJ) adenocarcinoma that has spread to areas near your stomach (locally advanced) or that has spread to other parts of your body (metastatic), and who have received a prior trastuzumab-based regimen.

It is not known if ENHERTU is safe and effective in children.

Please click here for full Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.

Important Safety Information,
including Boxed WARNINGS

What is the most important information I should know about ENHERTU?

ENHERTU can cause serious side effects, including:

Lung problems that may be severe, life-threatening or that may lead to death. If you develop lung problems your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs and symptoms:

  • Cough
  • Trouble breathing or shortness of breath
  • Fever
  • Other new or worsening breathing symptoms (e.g., chest tightness, wheezing)

Low white blood cell count (neutropenia). Low white blood cell counts are common with ENHERTU and can sometimes be severe. Your healthcare provider will check your white blood cell counts before starting ENHERTU and before starting each dose. Tell your healthcare provider right away if you develop any signs or symptoms of an infection or have fever or chills during treatment with ENHERTU.

Heart problems that may affect your heart’s ability to pump blood. Your healthcare provider will check your heart function before starting treatment with ENHERTU. Tell your healthcare provider right away if you get any of the following signs and symptoms:

  • New or worsening shortness of breath
  • Coughing
  • Feeling tired
  • Swelling of your ankles or legs
  • Irregular heartbeat
  • Sudden weight gain
  • Dizziness or feeling light-headed
  • Loss of consciousness

Your healthcare provider will check you for these side effects during your treatment with ENHERTU. Your healthcare provider may reduce your dose, delay treatment or completely stop treatment with ENHERTU if you have severe side effects.

Harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ENHERTU.

  • If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with ENHERTU.
  • Females who are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for at least 7 months after the last dose.
  • Males who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for at least 4 months after the last dose.

Before you receive ENHERTU, tell your healthcare provider about all of your medical conditions, including if you:

  • Have lung or breathing problems.
  • Have signs or symptoms of an infection.
  • Have or have had any heart problems.
  • Are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes into your breast milk. Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive ENHERTU?

  • You will receive ENHERTU into your vein through an intravenous (IV) line by your healthcare provider.
  • ENHERTU is given 1 time every three weeks (21-day treatment cycle).
  • Your healthcare provider will decide how many treatments you need.
  • Your healthcare provider may slow down or temporarily stop your infusion of ENHERTU if you have an infusion-related reaction, or permanently stop ENHERTU if you have severe infusion reactions.
  • If you miss a planned dose of ENHERTU, call your healthcare provider right away to schedule an appointment. Do not wait until the next planned treatment cycle.

What are the possible side effects of ENHERTU?

ENHERTU can cause serious side effects. See "What is the most important information I should know about ENHERTU?"

The most common side effects of ENHERTU, when used in people with breast cancer, include:

  • Nausea
  • Low white blood cell counts
  • Low red blood cell counts
  • Feeling tired
  • Vomiting
  • Hair loss
  • Increased liver function tests
  • Low platelet counts
  • Constipation
  • Decreased appetite
  • Diarrhea
  • Low levels of blood potassium
  • Cough

The most common side effects of ENHERTU, when used in people with stomach cancer, include:

  • Low red blood cell counts
  • Low white blood cell counts
  • Low platelet counts
  • Nausea
  • Decreased appetite
  • Increased liver function tests
  • Feeling tired
  • Diarrhea
  • Low levels of blood potassium
  • Vomiting
  • Constipation
  • Fever
  • Hair loss

ENHERTU may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.

These are not all of the possible side effects of ENHERTU. Call your doctor for medical advice about side effects. You may report side effects to Daiichi Sankyo at 1-877-437-7763 or to FDA at 1-800-FDA-1088.

What is ENHERTU?

ENHERTU is a prescription medicine used in adults to treat human epidermal growth factor receptor 2 (HER2)-positive:

  • Breast cancer that cannot be removed by surgery or that has spread to other parts of your body (metastatic), and who have received two or more prior anti-HER2 breast cancer treatments.

    ENHERTU was FDA approved for this use based on a clinical study that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

  • Stomach cancer called gastric or gastroesophageal junction (GEJ) adenocarcinoma that has spread to areas near your stomach (locally advanced) or that has spread to other parts of your body (metastatic), and who have received a prior trastuzumab-based regimen.

It is not known if ENHERTU is safe and effective in children.

Please click here for full Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.